Business · 27/02/2018
FDA to Host Public Workshop on Tissue Agnostic Therapies in Oncology for Orphan Drug Designation
The FDA is hosting a public workshop to discuss regulatory considerations for orphan drug designation for tissue agnostic therapies in oncology, with the goal of evaluating drugs for orphan designation and orphan exclusivity.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →